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Abstract
Background: Low-dose haloperidol is known to be effective for the prevention of postoperative nausea and
vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high
risk for PONV who require combination therapy. This study sought to identify which dose of haloperidol 1mg or
2mg could be combined with dexamethasone without adverse effects in high-risk patients undergoing
gynecological laparoscopic surgery.
Methods: Female adults (n = 150) with three established PONV risk factors based on Apfel’s score were randomized
into one of three study groups. At the end of anesthesia, groups H0, H1, and H2 were given intravenous (IV) saline,
haloperidol 1 mg, and haloperidol 2 mg, respectively. All patients were given dexamethasone 5 mg during the
induction of anesthesia. The overall early (0–2 h) and late (2–24 h) incidences of nausea, vomiting, rescue anti-emetic
administration, pain, and adverse effects (cardiac arrhythmias and extrapyramidal effects) were assessed postoperatively.
The sedation score was recorded in the postanesthesia care unit (PACU).
Results: The total incidence of PONV over 24 h was significantly lower in groups H1 (29 %) and H2 (24 %) than in
group H0 (54 %; P = 0.003), but there was no significant difference between groups H1 and H2. In the PACU, group H2
had a higher sedation score than groups H1 and H0 (P < 0.001).
Conclusions: For high-risk PONV patients undergoing gynecological laparoscopic surgery, when used with dexamethasone,
1-mg haloperidol was equally effective as 2 mg in terms of preventing PONV with the less sedative effect.
Trial Registration: ClinicalTrials.gov (NCT01639599).
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Background
Postoperative nausea and vomiting (PONV) is a common
complication of general anesthesia. In high-risk popula-
tions, such as females undergoing laparoscopic surgery
with opioid patient-controlled analgesia (PCA) for pain
control, the incidence can be as high as 79 % [1]. For these
high-risk patients, combination therapy using two or more
medications of different classes is more effective in
preventing PONV than the use of a single anti-emetic [2].
The most widely used combination in current clinical
practice consists of a 5-HT3 receptor antagonist and
dexamethasone [2]. Another choice is the combination
of dexamethasone and a butyrophenone, such as dro-
peridol, and this combination is known to be more cost-
effective [3]. However, the production of droperidol was
banned in several countries after the United States Food
and Drug Administration (FDA) issued a black-box
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warning due to QTc prolongation [4]. The exit of
droperidol from the market prompted a search for a
replacement, and many reports have considered halo-
peridol, another butyrophenone, as a substitute and the
commonly used doses were 1 or 2 mg IV [3, 5–9]. How-
ever, few studies have examined the dose-response of
haloperidol [10], especially in combination therapy for
high-risk patients. Therefore, we conducted a prospect-
ive, randomized, double-blinded study to identify the
appropriate dose of haloperidol (1mg vs. 2mg) to use in
combination with dexamethasone for preventing PONV
in high-risk patients undergoing gynecological laparo-
scopic surgery.
Methods
This study was approved by our local ethics committee
(Institutional Review Board of Catholic University Seoul
Saint Mary’s Hospital, Seoul, Korea, Ref. KC11MISI0335)
and registered at ClinicalTrials.gov (Ref: NCT01639599).
Written informed consent was obtained from all study
subjects. The study subjects were American Society of An-
esthesiologists (ASA) physical status I or II females, age
20–65 years, scheduled for gynecologic laparoscopic sur-
gery and intravenous (IV) PCA for postoperative pain
control. Based on Apfel’s simplified risk score, the patients
in this study had the following three standard PONV risk
factors: female, non-smoker, and use of opioid analgesics
after surgery. Exclusion criteria were as follows: known al-
lergy or intolerance to the study drug; history of cardiac
arrhythmia; psychiatric illness; chronic treatment with a
dopamine antagonist; use of opioids or steroids within 1
week of surgery; use of anti-emetic in the 24 h before the
study; unable to use the PCA device; gastrointestinal,
renal, or hepatic disease; and insulin-dependent diabetes
or obesity with a body mass index >35 kg/m2.
Using computer-generated codes placed in sequen-
tially numbered, opaque envelopes, the enrolled pa-
tients were assigned randomly to one of three groups:
group H0 = saline, group H1 = haloperidol 1 mg, and
group H2 = haloperidol 2 mg. A nurse anesthetist not
involved in the treatment opened the envelopes and
prepared the study drugs in identical syringes with a
total volume of 2 mL (diluted with saline). The patients
and attending anesthesiologists were blinded to the
group assignments. Staff who remained blind to the
group assignment made the postoperative evaluations.
General anesthesia was induced with 0.5–1 μg/kg
remifentanil and 1–2 mg/kg propofol. Orotracheal
intubation was performed after administering 0.8 mg/kg
rocuronium. All patients received 5-mg dexamethasone
IV during induction. Anesthesia was maintained with
0.05–0.15 μg/kg/min remifentanil and 1.2-2 % sevoflur-
ane (endotidal concentration) in 50 % air/oxygen to keep
the bispectral index (BIS) value at 40–60. Ventilation
was controlled mechanically and adjusted to maintain
end-tidal CO2 values of 30–40 mmHg. Additional rocur-
onium was administered as required. The laparoscopy
was performed under video guidance with three punc-
tures in the abdomen. Approximately 30 min before the
end of anesthesia, the study drug was administered.
Residual neuromuscular blockade was antagonized with
10-mg pyridostigmine and 0.4-mg glycopyrrolate IV.
The trachea was extubated when the patient was awake.
No other opioid was administered during the operation.
On arriving at the postanesthesia care unit (PACU), all
patients were given acetaminophen 1 g IV for postopera-
tive pain control. The patients were administered IV
PCA when discharged from the PACU after 2 h. The
PCA regimen consisted of 1-mg fentanyl and 120-mg
ketorolac (total volume including saline 100 mL) and
was programmed to deliver 1 mL/h as a background
infusion and 1 mL per demand, with a 10-min lockout.
Two postoperative time periods were evaluated: 0–2
and 2–24 h after surgery. For the first 2 h, a trained
investigator without knowledge of the study group as-
signment measured the following variables in the PACU:
incidence of nausea and vomiting (or retching), pain
intensity, rescue anti-emetics, rescue analgesics and inci-
dence of adverse effects such as cardiac arrhythmias or
neurological side effects. Nausea was defined subjectively
unpleasant sensation associated with awareness of the
urge to vomit. Nausea was also graded as tolerable or
intolerable. Rescue medication (4-mg ondansetron) was
administered to any patient who experienced intolerable
nausea or vomiting, or who requested rescue anti-emetics.
The primary outcome was the incidence of nausea or
vomiting during the study period.
Postoperative pain intensity was measured using a 10-cm
visual analogue scale (VAS; 0 = no pain and 10 = the worst
pain imaginable). When a patient complained of more pain
and requested analgesia, 30 mg ketorolac IV was given
(a maximum of 120 mg/day). After discharge from the
PACU, data were collected by a blinded investigator
every 6 h.
The standard lead ECG was monitored continuously at a
paper speed of 25 mm/s and an amplification of 0.1 mV/
mm. Heart rate was calculated from three RR intervals
preceding the measured QT intervals. The QT intervals
were measured manually from the onset of the QRS com-
plexes to the end of the T wave and corrected for the pa-
tient’s heart rate using Bazett’s formula QTc ¼ QT= ﬃﬃﬃﬃﬃﬃRRp .
The QTc interval was measured pre-operatively and 10
min after each patient arrived in the PACU.
The level of sedation was evaluated immediately, 30,
60, 90, and 120 min after arriving in the PACU. Each
patient was asked to assess her level of sedation using
a 10-cm VAS (0 = wide awake and 10 = maximally
asleep) [11, 12].
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Statistical analysis
The primary endpoint of this study was the incidence of
PONV during the study period. In a preliminary study
of 15 patients who received dexamethasone and had the
same inclusion and exclusion criteria, 60 % of the pa-
tients suffered from nausea and vomiting for up to 24 h
after gynecological laparoscopic surgery. To obtain an
80 % chance of identifying a 30 % reduction of PONV
incidence during the first 24 h after surgery at the level
α = 0.05 (two-sided), 43 patients were required for each
group. Considering potential dropouts, 50 patients were
included in each group. One-way analysis of variance
(ANOVA) was used to examine differences in the para-
metric data among the three groups. If a significant differ-
ence was found, the Bonferroni test was used to detect the
inter-group differences. Changes in the sedation VAS
scores over time were analyzed using repeated-measures
ANOVA with a post hoc test. Categorical data were ana-
lyzed using the chi-square test. The Bonferroni correction
was used for all multiple comparisons. P < 0.05 was con-
sidered statistically significant. SPSS ver. 15.0 for Windows
(SPSS, Chicago, IL, USA) was used for the analyses.
Results
Of the 150 patients registered for the study, one was
excluded due to an intra-operative conversion to lapar-
otomy (Fig. 1). The remaining 149 patients, consisting of
50, 49, and 50 patients in groups H0, H1, and H2,
respectively, completed the study. The patient character-
istics, PONV risk factors, type of surgery, duration of
anesthesia, intra-operative remifentanil use, 24-h postop-
erative PCA fentanyl use, postoperative pain severity,
and rescue analgesic requirements were similar among
the three groups (Table 1).
Overall, the frequency of PONV within 24 h postoper-
atively was lower in groups H1 and H2 than in group
H0, while there was no statistical difference between
groups H1 and H2 (29, 24, and 54 % in groups H1, H2,
Fig. 1 CONSORT diagram showing the flow of participants
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and H0, respectively; P = 0.003). Table 2 summarizes the
results at each postoperative time point.
In the PACU (0–2 h), group H1 had a lower incidence
of PONV and reduced requirements for rescue anti-
emetics than group H0, while group H2 did not differ
significantly from group H0. In the ward (2–24 h), the
incidence of PONV was lower in groups H1 and H2
than in group H0, but there was no statistically signifi-
cant difference between groups H1 and H2 (22 % in
group H1 and 20 % in group H2 vs. 42 % in group H0).
The change in the sedation score in the PACU clearly
differed among the groups according to the dose of
haloperidol. Group H2 had an overall higher sedation
score than groups H1 and H0 over the 2-h observation
period (P < 0.001, Fig. 2), while there was no significant
difference between groups H1 and H0. In addition, three
patients in group H2 required treatment with ephedrine
in the PACU, due to hypotension (systolic 75–80/dia-
stolic 50–55 mmHg).
The QTc intervals before administering the study drug
were similar among the groups (group H0, 423.85 ± 21.94
ms; group H1, 425.23 ± 0.21 ms; and group H2, 426.35 ±
15.13 ms). The QTc interval measured in the PACU also
did not differ among the groups (group H0, 426.75 ± 19.64
ms; group H1, 430.67 ± 21.92 ms; and group H2, 431.95 ±
23.14 ms). No cardiac arrhythmias were observed in the
PACU. No patient showed evidence of twitching, dystonia,
akathisia, or other extrapyramidal reactions during the
24-h postoperative observation period.
Discussion
In this randomized, double-blind study, both 1- and
2-mg haloperidol, in combination with dexamethasone,
had PONV-preventing effects during the first 24 h post-
operative, compared with dexamethasone monotherapy.
However, 2-mg haloperidol resulted in more sedation of
patients in the PACU than the 1-mg dose.







Age (year) 40 (20–60) 39 (20–60) 41 (21–58)
Weight (kg) 56.9 (5.7) 55.0 (7.9) 54.4 (5.3)
Height (cm) 158.7 (4.9) 159.1 (5.5) 157.3 (5.5)
ASA I/II 40/10 41/8 39/11
PONV or motion sickness history 26 (52 %) 28 (57 %) 28 (56 %)
Anesthesia duration (min) 150.3 (43.1) 157.9 (39.4) 156.4 (31.4)
Remifentanil consumption (μg) 104.7 (36.2) 97.2 (31.3) 92.5 (29.2)
Surgical type
Lap. ovarian cystectomy 17 (34 %) 12 (24 %) 13 (26 %)
Lap. hysterectomy 23 (46 %) 22 (45 %) 26 (52 %)
Diagnostic laparoscopy 5 (10 %) 11 (22 %) 6 (12 %)
Lap. myomectomy 4 (8 %) 3 (6 %) 4 (8 %)
Lap. adhesiolysis 1 (2 %) 1 (2 %) 1 (2 %)
PCA fentanyl consumption
for 24 h (μg)
470.1 (105.5) 465.6 (102.6) 467.8 (99.5)
Postoperative pain
0-2 h 4.9 (1.7) 4.8 (1.8) 4.6 (2.1)
2-24 h 2.2 (2.1) 2.8 (1.6) 2.2 (1.9)
Rescue analgesic requirements 15 (30 %) 11 (22 %) 10 (20 %)
Values are means (SD) or number (proportion). No statistically significant
difference was observed among the groups
Group H0 = saline, H1 = haloperidol 1 mg, and H2 = haloperidol 2 mg
PONV postoperative nausea and vomiting; Lap laparoscopic; PCA
patient-controlled analgesia
Table 2 PONV outcomes
Group H0 Group H1 Group H2
(n = 50) (n = 49) (n = 50) P*
Early time (0–2 h)
Nausea 15 (30 %) 5 (10 %)† 9 (18 %) 0.04
Vomiting 7 (14 %) 3 (6 %) 4 (8 %) 0.37
Total PONV 17 (34 %) 5 (10 %)† 10 (20 %) 0.02
Rescue anti-emetics 12 (24 %) 3 (6 %)† 6 (12 %) 0.03
Late time (2–24 h)
Nausea 17 (34 %) 10 (20 %) 9 (18 %) 0.13
Vomiting 6 (12 %) 5 (10 %) 3 (6 %) 0.57
Total PONV 21 (42 %) 11 (22 %) 10 (20 %) 0.03
Rescue anti-emetics 11 (22 %) 7 (14 %) 7 (14 %) 0.48
Values are numbers (proportion). Groups H0 = saline, H1 = haloperidol 1 mg,
and H2 = haloperidol 2 mg
PONV postoperative nausea and vomiting
*Unadjusted P value
†P < 0.017, compared with group H0
Fig. 2 Postanesthesia care unit-sedation scores recorded using a 10
cm visual analogue scale (VAS; 0 = wide awake and 10 =maximally
asleep) in patients receiving saline (▲), haloperidol 1 mg (●) or
haloperidol 2mg (■). *P < 0.05 compared with saline. †P < 0.05
compared with haloperidol 1 mg
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According to Apfel’s risk score, each of the following risk
factors increases the risk of PONV by 20 %: female, non-
smoker, postoperative opioid use, and a history of PONV
or motion sickness [1]. All patients enrolled in our study
had an Apfel’s risk score ≥3, so the anticipated incidence of
PONV exceeded 60 %. Additionally, pelvic surgery is
known to increase risk for PONV. According to the con-
sensus guidelines for managing PONV, these high-risk pa-
tients require combination therapy using drugs from two
or three different classes [13]. The combination used most
commonly is dexamethasone plus a 5-HT3 antagonist,
while the combination of dexamethasone and a butyro-
phenone compound is known to be more cost-effective.
Many studies have investigated haloperidol, another bu-
tyrophenone. In a meta-analysis of 23 randomized trials,
the dosage of haloperidol suggested to be effective at pre-
venting PONV was 0.5–4 mg [14]. However, the delivery
methods in this analysis included intravenous (IV) and
intramuscular (IM) routes, and this lack of uniformity
meant that a precise dose-response relationship could not
be identified. Furthermore, although many recent clinical
trials have reported on the anti-emetic effect of haloperi-
dol and that the commonly used doses were either 1 or 2
mg IV [3, 5–9], there have been few dose-response studies
within this dose range. In our study, we chose 1 mg as the
minimum dose based on Dagtekin’s research [15]. They
reported that 10 μg/kg haloperidol had a limited effect in
female subjects compared with the placebo. The dose
range of haloperidol used in that study was ~550-830 μg
considering the participants’ weights. Thus, given that a
dose less than 1 mg was ineffective in female patients, we
used 1 mg as the minimum dose in our study.
Parlow et al. compared the anti-emetic effect of 1- or 2-
mg haloperidol IM [10]. However, their study design dif-
fered from ours in that they enrolled non-high-risk patients
undergoing spinal anesthesia. By contrast, we sought to de-
termine the appropriate dosage of haloperidol in combin-
ation with dexamethasone, not causing side effects, for
high-risk patients requiring combination therapy after gen-
eral anesthesia.
In our study, 1- and 2-mg haloperidol with dexametha-
sone more effectively reduced PONV compared with dexa-
methasone alone, while no significant differences were
detected between the two groups. Interestingly, the inci-
dence of PONV in the PACU was slightly higher in group
H2 than in group H1 (20 % vs. 10 %: not statistically
significant).
In general, various factors can affect postoperative
sedation, including the type and duration of anesthesia, pa-
tient age, and the use of narcotics in the PACU. In our
study, short-acting sevoflurane and remifentanil were used,
and the depth of anesthesia was maintained at BIS 40–60.
Pain control in the PACU was achieved with non-narcotic
analgesics, and opioid PCA was applied at the time of
discharge from the PACU. The duration of anesthesia and
age distribution of the patients were similar among the
three study groups. These facts suggest that the observed
difference in sedation was probably attributable to the dos-
age of haloperidol. In our study, the sedation scores of pa-
tients in group H2 were significantly higher than those in
group H1, as well as in the control group, while there was
no difference between group H1 and the control group.
The differences in sedation scores became more apparent
90 and 120 min after arriving in the PACU, when the effect
of the inhaled anesthetics had ended. These results do not
agree with a previous study in which 2-mg haloperidol did
not have a sedative effect, compared with normal saline [6].
In that study, however, the level of sedation was evaluated
only once (30 min after surgery), and no specific data on
sedation were presented.
This delayed sedative effect is likely related to the long
plasma half-life of haloperidol, compared with droperi-
dol (18 h for haloperidol vs. 2 h for droperidol) [16, 17].
Therefore, it has been suggested that the drug has a lon-
ger duration of action, even when administered at low
doses [18]. Forsman reported that the sedative effects
reached a maximum during the first 1-h distribution
period after IV administration [19]. This sedative effect
would increase in the PACU when combined with
residual anesthetics following general anesthesia. There-
fore, the dose of haloperidol in patients receiving general
anesthesia should be considered carefully.
Buttner et al. reported that only 1 of 806 patients who re-
ceived 0.25–5-mg haloperidol IV experienced extrapyram-
idal symptoms with a 4-mg dose [14]. In our study, no
patients showed neurological side effects during the post-
operative 24 h. In the same report, 1397 patients received
various haloperidol regimens, but no cardiac arrhythmia
was reported [14]. In our study, the QTc interval was not
significantly different among the groups after administering
the study medication, and there was no evidence of any ad-
verse effect on cardiac rhythm during the first postoperative
2 h. However, our study design cannot lead one to the con-
clusion that low-dose haloperidol is entirely safe. A large
number of subjects are necessary to exclude all possible
adverse effects and so this drug should still be used with
caution in critically ill patients.
There were a number of limitations to our study. First,
there was no complete control group. All patients, in-
cluding the control group, were administered 5-mg
dexamethasone IV during induction. It was considered
unethical to exclude high-risk patients from prophylactic
management of PONV. Furthermore, these two anti-
emetics have different mechanisms of action. Haloperidol
acts by antagonizing D2 receptors in the chemoreceptor
trigger zone of the medulla [20], while dexamethasone
activates glucocorticoid receptors in the solitary tract nu-
cleus of the medulla [21]. Second, the primary endpoint of
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this study was the detection of differences in anti-emetic
effect, but not sedative effect, according to the haloperidol
dosage. Consequently, to measure the sedated state, a
simple VAS score was used instead of more sophisticated
methods that might be able to detect more subtle effects
of the drug dosage. Nevertheless, our results are justified
since a VAS has been proven valid for measuring sedation
change over time and has been used in many studies
[11, 12]. Third, our study had a relatively small sample size
compared to a complete dose-response study. Thus, our
results must be considered as exploratory results, rather
than confirmatory results. In order to generalize our
results, a full dose-response study may be necessary.
Conclusions
For high-risk patients requiring combination anti-emetic
therapy after general anesthesia, when used with dexa-
methasone, 1-mg haloperidol was more appropriate in
terms of preventing PONV with less sedative effect than
2-mg haloperidol. Importantly, increasing the dose beyond
1 mg did not have additional positive effects, but might
induce negative side effects. However, in order to confirm
our exploratory results, a well-designed, large-sample,
dose-response study is necessary in future.
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